Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies

被引:65
作者
Podhorna, Jana [1 ]
Krahnke, Tillmann [2 ]
Shear, Michael [3 ]
Harrison, John E. [4 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Binger Str 173, D-55218 Ingelheim, Germany
[2] Cogitars GmbH, Heidelberg, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam, Netherlands
来源
ALZHEIMERS RESEARCH & THERAPY | 2016年 / 8卷
基金
加拿大健康研究院;
关键词
ADAS-Cog; Enrichment markers; Mild Alzheimer's disease; Mild cognitive impairment; t-Tau/A beta ratio; Decline over time; MENTAL-STATE-EXAMINATION; CLINICAL-TRIALS; CRITERIA; DECLINE;
D O I
10.1186/s13195-016-0170-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in patients with mild to moderate AD. Attempts to improve its properties for early AD by removing items prone to ceiling and/or by adding cognitive measures known to be impaired early have yielded a number of ADAS-Cog variants. Using Alzheimer's Disease Neuroimaging Initiative data, we compared the performance of the 3-, 5-, 11- and 13-item ADAS-Cog variants in subjects with early AD. Given the interest in enrichment strategies, we also examined this aspect with a focus on cerebrospinal fluid (CSF) markers. Methods: Subjects with mild cognitive impairment (MCI) and mild AD with available ADAS-Cog 13 and CSF data were analysed. The decline over time was defined by change from baseline. Direct cross-comparison of the ADAS-Cog variants was performed using the signal-to-noise ratio (SNR), with higher values reflecting increased sensitivity to detect change over time. Results: The decline over time on any of the ADAS-Cog variants was minimal in subjects with MCI. Approximately half of subjects with MCI fulfilled enrichment criteria for positive AD pathology. The impact of enrichment was detectable but subtle in MCI. The annual decline in mild AD was more pronounced but still modest. More than 90 % of subjects with mild AD had positive AD pathology. SNRs were low in MCI but greater in mild AD. The numerically largest SNRs were seen for the ADAS-Cog 5 in MCI and for both the 5- and 13-item ADAS-Cog variants in mild AD, although associated confidence intervals were large. Conclusions: The possible value of ADAS-Cog expansion or reduction is less than compelling, particularly in MCI. In mild AD, adding items known to be impaired at early stages seems to provide more benefit than removing items on which subjects score close to ceiling.
引用
收藏
页数:13
相关论文
共 39 条
  • [11] Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Grundman, M
    Petersen, RC
    Ferris, SH
    Thomas, RG
    Aisen, PS
    Bennett, DA
    Foster, NL
    Jack, CR
    Galasko, DR
    Doody, R
    Kaye, J
    Sano, M
    Mohs, R
    Gauthier, S
    Kim, HT
    Jin, S
    Schultz, AN
    Schafer, K
    Mulnard, R
    van Dyck, CH
    Mintzer, J
    Zamrini, EY
    Cahn-Weiner, D
    Thal, LJ
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (01) : 59 - 66
  • [12] Biological markers of amyloid β-related mechanisms in Alzheimer's disease
    Hampel, Harald
    Shen, Yong
    Walsh, Dominic M.
    Aisen, Paul
    Shaw, Les M.
    Zetterberg, Henrik
    Trojanowski, John Q.
    Blennow, Kaj
    [J]. EXPERIMENTAL NEUROLOGY, 2010, 223 (02) : 334 - 346
  • [13] Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis
    Han, L
    Cole, M
    Bellavance, F
    McCusker, J
    Primeau, F
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2000, 12 (02) : 231 - 247
  • [14] Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment
    Hansson, Oskar
    Zetterberg, Henrik
    Buchhave, Peder
    Andreasson, Ulf
    Londos, Elisabet
    Minthon, Lennart
    Blennow, Kaj
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 23 (05) : 316 - 320
  • [15] Putting the Alzheimer's cognitive test to the test I: Traditional psychometric methods
    Hobart, Jeremy
    Cano, Stefan
    Posner, Holly
    Selnes, Ola
    Stern, Yaakov
    Thomas, Ronald
    Zajicek, John
    [J]. ALZHEIMERS & DEMENTIA, 2013, 9 (01) : S4 - S9
  • [16] Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
    Jack, Clifford R., Jr.
    Knopman, David S.
    Jagust, William J.
    Shaw, Leslie M.
    Aisen, Paul S.
    Weiner, Michael W.
    Petersen, Ronald C.
    Trojanowski, John Q.
    [J]. LANCET NEUROLOGY, 2010, 9 (01) : 119 - 128
  • [17] Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
    Liu, Chia-Chan
    Kanekiyo, Takahisa
    Xu, Huaxi
    Bu, Guojun
    [J]. NATURE REVIEWS NEUROLOGY, 2013, 9 (02) : 106 - 118
  • [18] MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  • [19] Mendiondo MS, 2000, STAT MED, V19, P1607, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1607::AID-SIM449>3.0.CO
  • [20] 2-O